Preterm Birth Diagnostic

About Milu Labs

Milu Labs is an early-stage, privately-held diagnostics company targeting significant gaps in women's health through two innovative technology platforms: exosome-based 'bio-fingerprinting' and integrated multiomics analysis. The company's lead program is a non-invasive diagnostic test for early prediction of preterm birth, a major global health challenge. Led by a team with strong backgrounds in healthcare investment, diagnostics commercialization, and global strategy, the company is positioned to develop and commercialize these technologies, initially focusing on the Asian market before expanding worldwide.

Therapeutic Areas